Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Bergisch Gladbach – page 104

1 418 clinical trials in Bergisch Gladbach, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Bergisch Gladbach at a glance
1 418
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 418 trials in Bergisch Gladbach

Open in trial search

Short stature+3

Not recruiting

Study Comparing Somapacitan and Somatropin for Growth in Children with Short Stature Due to Small for Gestational Age, Turner Syndrome, Noonan Syndrome, or Idiopathic Short Stature

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Somapacitan
  • Sponsor:Novo Nordisk A/S

Study Comparing Teclistamab with Daratumumab, Pomalidomide, and Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Janssen Cilag International

Glioblastoma

Not recruiting

Study of Troriluzole and ADI-PEG-20 for Patients with Newly Diagnosed and Recurrent Glioblastoma

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Elrelesertib
  • Sponsor:Global Coalition For Adaptive Research Inc.

Plasma cell myeloma

Not recruiting

Study Comparing Idecabtagene Vicleucel and Lenalidomide Maintenance Therapy for Adults with Newly Diagnosed Multiple Myeloma After Stem Cell Transplant

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Lenalidomide
  • Sponsor:Celgene Corp.

Study on Regorafenib and Nivolumab for Patients with Advanced Gastro-Oesophageal Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Nivolumab
  • Sponsor:Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH

Study Comparing Ibrutinib, Venetoclax, and Obinutuzumab for Untreated Chronic Lymphocytic Leukemia Patients

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Ibrutinib
  • Sponsor:University Of Cologne

Atrial fibrillation+2

Not recruiting

Study on Asundexian and Apixaban for Preventing Stroke in Adults with Atrial Fibrillation at Risk for Stroke

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Apixaban
  • Sponsor:Bayer AG

Obesity+1

Not recruiting

Study on the Safety and Effects of AZD9550 for Overweight and Obese Patients with Non-Alcoholic Steatohepatitis (NASH) with or without Type 2 Diabetes

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Ascorbic Acid
  • Sponsor:AstraZeneca AB

Laparotomy

Not recruiting

Study on Oral Lidocaine for Reducing Gastrointestinal Issues in Patients After Abdominal Surgery

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Lidocaine Hydrochloride Monohydrate
  • Sponsor:Orexa B.V.

Lupus nephritis

Not recruiting

Study on Zetomipzomib for Patients with Active Lupus Nephritis

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Methylprednisolone
  • Sponsor:Kezar Life Sciences Inc.

Malignant melanoma

Not recruiting

Study of mRNA-4157 and Pembrolizumab for Patients with High-Risk Stage II-IV Melanoma

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:MRNA-4157
  • Sponsor:Merck Sharp & Dohme LLC

Study of Dostarlimab and Drug Combination for Patients with Untreated Resectable Colon Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Glaxosmithkline Research & Development Limited

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Bergisch Gladbach

What the registry says about research in the country

01 Breast Cancer Research

Innovative clinical trials focusing on hormone receptor-positive (HR+) and HER2-negative breast cancer treatments, exploring new therapeutic combinations to improve patient outcomes.

  • Early-stage breast cancer therapies
  • Advanced breast cancer treatments
  • Endocrine therapy combinations

Studies evaluating breakthrough medications like ribociclib, elacestrant, and abemaciclib in combination with standard treatments.

02 Prostate Cancer Studies

Comprehensive research targeting metastatic prostate cancer, including both castration-resistant and castration-sensitive forms of the disease.

  • Advanced hormone therapy approaches
  • Novel treatment combinations
  • Biochemical recurrence management

Trials examining innovative treatments including darolutamide and new therapeutic protocols for different stages of disease progression.

03 Supportive Care Research

Studies addressing treatment-related side effects, particularly focusing on vasomotor symptoms in cancer patients undergoing hormone therapy.

  • Quality of life improvements
  • Side effect management
  • Treatment optimization

Investigation of new compounds like elinzanetant for managing therapy-induced symptoms in cancer patients.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.